What is Semler Scientific Inc's earnings per share (EPS)?

Semler Scientific Inc (SMLR) reported diluted earnings per share of $5.13 for fiscal year 2024. This represents a 95.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Semler Scientific Inc Financials

SMLR

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2025 Currency USD FYE December

This page shows Semler Scientific Inc (SMLR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SMLR FY2024 2026-04-22

In FY2024, Semler's dominant mechanic was a balance-sheet transformation that dwarfed the change in its core operations.

After several years when cash generation and reported profit were close, net income rose to $40.9M while operating cash flow was only $24.4M. Because revenue was lower in that same year, the gap points to earnings lifted outside the core operation rather than a sudden improvement in how the business turns sales into cash; the operating engine itself looks steadier than headline profit suggests.

The biggest structural shift is asset redeployment: total assets jumped to $239.8M after an unusually large investing outflow, even though the operating engine still generates cash on a much smaller scale. With total liabilities at just $9.1M, the larger balance sheet appears to have been built mainly with new equity capital rather than debt, which makes dilution part of the economic tradeoff.

The core business still looks asset-light with very high gross margin: gross margin stayed above 89.0% and FY2024 capital spending was only $51K. That combination says this company does not need much physical reinvestment to operate, so changes in operating profit mostly reflect revenue mix and overhead control rather than heavy capital needs.

Financial Health Signals

Financial Health Score 78/100

Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Semler Scientific Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Semler Scientific Inc has an operating margin of 37.2%, meaning the company retains $37 of operating profit per $100 of revenue. This strong profitability earns a score of 95/100, reflecting efficient cost management and pricing power. This is up from 32.6% the prior year.

Growth

Semler Scientific Inc's revenue declined 17.4% year-over-year, from $68.2M to $56.3M. This contraction results in a growth score of 30/100.

Leverage

Semler Scientific Inc carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 85/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.59, Semler Scientific Inc holds $3.59 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.

Cash Flow

Semler Scientific Inc converts 43.3% of revenue into free cash flow ($24.4M). This strong cash generation earns a score of 97/100.

Returns

Semler Scientific Inc earns a strong 17.7% return on equity (ROE), meaning it generates $18 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 80/100. This is down from 28.7% the prior year.

Altman Z-Score Safe

21.73

Semler Scientific Inc scores 21.73, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($310.7M) relative to total liabilities ($9.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Semler Scientific Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

0.60x

For every $1 of reported earnings, Semler Scientific Inc generates $0.60 in operating cash flow ($24.4M OCF vs $40.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$56.3M

YoY-17.4%

5Y CAGR+11.4%

10Y CAGR+31.5%

Semler Scientific Inc generated $56.3M in revenue in fiscal year 2024. This represents a decrease of 17.4% from the prior year.

EBITDA

$21.5M

YoY-5.9%

5Y CAGR+13.7%

Semler Scientific Inc's EBITDA was $21.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 5.9% from the prior year.

Net Income

$40.9M

YoY+98.7%

5Y CAGR+22.1%

Semler Scientific Inc reported $40.9M in net income in fiscal year 2024. This represents an increase of 98.7% from the prior year.

EPS (Diluted)

$5.13

YoY+95.1%

5Y CAGR+22.2%

Semler Scientific Inc earned $5.13 per diluted share (EPS) in fiscal year 2024. This represents an increase of 95.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$24.4M

YoY+16.1%

5Y CAGR+14.2%

Semler Scientific Inc generated $24.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 16.1% from the prior year.

Cash & Debt

$8.8M

YoY-84.6%

5Y CAGR+2.6%

10Y CAGR+7.8%

Semler Scientific Inc held $8.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

10M

YoY+38.8%

5Y CAGR+7.9%

10Y CAGR+7.3%

Semler Scientific Inc had 10M shares outstanding in fiscal year 2024. This represents an increase of 38.8% from the prior year.

Margins & Returns

Gross Margin

91.5%

YoY+1.8pp

5Y CAGR+2.7pp

10Y CAGR+10.6pp

Semler Scientific Inc's gross margin was 91.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1.8 percentage points from the prior year.

Operating Margin

37.2%

YoY+4.5pp

5Y CAGR+4.5pp

10Y CAGR+156.6pp

Semler Scientific Inc's operating margin was 37.2% in fiscal year 2024, reflecting core business profitability. This is up 4.5 percentage points from the prior year.

Net Margin

72.7%

YoY+42.5pp

5Y CAGR+26.6pp

10Y CAGR+196.9pp

Semler Scientific Inc's net profit margin was 72.7% in fiscal year 2024, showing the share of revenue converted to profit. This is up 42.5 percentage points from the prior year.

Return on Equity

17.7%

YoY-11.0pp

5Y CAGR-97.7pp

10Y CAGR+149.1pp

Semler Scientific Inc's ROE was 17.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 11.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$4.8M

YoY-17.0%

Semler Scientific Inc invested $4.8M in research and development in fiscal year 2024. This represents a decrease of 17.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$51K

YoY-85.2%

5Y CAGR-21.8%

10Y CAGR+18.9%

Semler Scientific Inc invested $51K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 85.2% from the prior year.

SMLR Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$56.3M-17.4%	$68.2M+20.3%	$56.7M+6.9%	$53.0M+37.4%	$38.6M+17.8%	$32.8M
Cost of Revenue	$4.8M-31.9%	$7.0M+64.3%	$4.3M-30.5%	$6.1M+82.4%	$3.4M-8.3%	$3.7M
Gross Profit	$51.5M-15.8%	$61.2M+16.7%	$52.4M+11.8%	$46.9M+33.1%	$35.2M+21.1%	$29.1M
R&D Expenses	$4.8M-17.0%	$5.8M+31.0%	$4.4M	N/A	N/A	N/A
SG&A Expenses	$12.7M-10.9%	$14.3M+12.2%	$12.7M+37.9%	$9.2M+44.2%	$6.4M-7.9%	$7.0M
Operating Income	$20.9M-5.9%	$22.3M+29.4%	$17.2M-11.5%	$19.4M+21.8%	$16.0M+49.1%	$10.7M
Interest Expense	N/A	N/A	$494K+4840.0%	$10K-47.4%	$19K+850.0%	$2K
Income Tax	$7.0M+98.6%	$3.5M+4.5%	$3.4M+50.8%	$2.2M-9.9%	$2.5M+156.6%	-$4.4M
Net Income	$40.9M+98.7%	$20.6M+43.7%	$14.3M-16.8%	$17.2M+23.0%	$14.0M-7.1%	$15.1M
EPS (Diluted)	$5.13+95.1%	$2.63+46.9%	$1.79-15.6%	$2.12+21.8%	$1.74-7.4%	$1.88

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$7.5M-8.8%	$8.2M-7.0%	$8.8M-28.8%	$12.4M-8.1%	$13.5M-6.6%	$14.5M-9.0%	$15.9M+5.6%	$15.1M
Cost of Revenue	$636K-13.9%	$739K-21.1%	$937K-14.9%	$1.1M-4.8%	$1.2M-7.9%	$1.3M+0.6%	$1.2M-63.2%	$3.4M
Gross Profit	$6.9M-8.3%	$7.5M-5.3%	$7.9M-30.2%	$11.3M-8.4%	$12.4M-6.5%	$13.2M-9.9%	$14.7M+25.6%	$11.7M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$8.0M+55.9%	$5.1M+5.0%	$4.9M+29.7%	$3.8M+20.5%	$3.1M+5.6%	$3.0M+3.4%	$2.9M-12.1%	$3.3M
Operating Income	-$5.4M-162.5%	-$2.1M+93.4%	-$31.1M-978.1%	$3.5M-30.1%	$5.1M-5.3%	$5.3M-23.3%	$7.0M+176.7%	$2.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$6.9M-49.4%	$13.6M+234.1%	-$10.2M-401.8%	$3.4M+339.8%	$766K-32.0%	$1.1M-34.7%	$1.7M+222.4%	-$1.4M
Net Income	$16.9M-74.7%	$66.9M+203.4%	-$64.7M-321.5%	$29.2M+420.7%	$5.6M+50890.9%	$11K-99.8%	$6.1M+43.9%	$4.2M
EPS (Diluted)	$1.07-78.8%	$5.04+174.8%	$-6.74	N/A	$0.72	$0.00-100.0%	$0.78	N/A

SMLR Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$239.8M+207.2%	$78.1M+24.5%	$62.7M+23.7%	$50.7M+46.3%	$34.6M+89.4%	$18.3M
Current Assets	$22.7M-65.6%	$65.9M+34.8%	$48.9M+7.4%	$45.5M+71.2%	$26.6M+132.5%	$11.4M
Cash & Equivalents	$8.8M-84.6%	$57.2M+148.5%	$23.0M-38.3%	$37.3M+69.0%	$22.1M+185.2%	$7.7M
Inventory	$358K-19.6%	$445K-5.1%	$469K-14.7%	$550K+61.8%	$340K	N/A
Accounts Receivable	$4.4M-28.5%	$6.1M+57.7%	$3.9M+7.3%	$3.6M+28.9%	$2.8M-19.4%	$3.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.1M+44.8%	$6.3M-10.6%	$7.0M+36.9%	$5.1M+5.8%	$4.8M-7.1%	$5.2M
Current Liabilities	$6.3M+1.8%	$6.2M-9.6%	$6.9M+40.5%	$4.9M+8.1%	$4.5M-13.3%	$5.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$230.8M+221.4%	$71.8M+29.0%	$55.7M+22.2%	$45.5M+52.9%	$29.8M+127.9%	$13.1M
Retained Earnings	$100.7M+68.4%	$59.8M+52.5%	$39.2M+57.5%	$24.9M+224.4%	$7.7M+221.1%	-$6.3M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$596.7M+14.2%	$522.6M+78.1%	$293.4M+22.4%	$239.8M+160.1%	$92.2M+8.7%	$84.8M+1.1%	$83.9M+7.4%	$78.1M
Current Assets	$53.5M+144.3%	$21.9M+18.7%	$18.5M-18.7%	$22.7M+5.6%	$21.5M-9.3%	$23.7M-67.1%	$71.9M+9.0%	$65.9M
Cash & Equivalents	$10.2M-24.5%	$13.5M+38.5%	$9.7M+10.4%	$8.8M+34.3%	$6.6M-10.4%	$7.3M-88.3%	$62.8M+9.7%	$57.2M
Inventory	$485K-13.1%	$558K+50.8%	$370K+3.4%	$358K-5.8%	$380K-1.3%	$385K-5.6%	$408K-8.3%	$445K
Accounts Receivable	$2.6M-9.6%	$2.8M-9.8%	$3.1M-28.3%	$4.4M-34.3%	$6.7M-10.7%	$7.5M+21.8%	$6.1M+0.1%	$6.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$136.9M-1.6%	$139.2M+5.6%	$131.8M+1351.4%	$9.1M+32.7%	$6.8M+7.1%	$6.4M+7.4%	$6.0M-5.1%	$6.3M
Current Liabilities	$27.2M-26.0%	$36.8M+3.1%	$35.7M+465.0%	$6.3M-7.7%	$6.8M+7.5%	$6.4M+7.8%	$5.9M-4.8%	$6.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$459.7M+19.9%	$383.4M+137.1%	$161.7M-29.9%	$230.8M+170.3%	$85.4M+8.9%	$78.4M+0.6%	$77.9M+8.5%	$71.8M
Retained Earnings	$119.8M+16.4%	$102.9M+185.9%	$36.0M-64.3%	$100.7M+40.8%	$71.5M+8.5%	$65.9M0.0%	$65.9M+10.2%	$59.8M

SMLR Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$24.4M+14.4%	$21.3M+22.1%	$17.5M+8.8%	$16.1M+6.2%	$15.1M+18.7%	$12.7M
Capital Expenditures	$51K-85.2%	$345K-27.5%	$476K+49.7%	$318K+113.4%	$149K-14.4%	$174K
Free Cash Flow	$24.4M+16.1%	$21.0M+23.5%	$17.0M+7.9%	$15.7M+5.2%	$15.0M+19.2%	$12.6M
Investing Cash Flow	-$190.0M-1132.7%	$18.4M+168.6%	-$26.8M-3152.7%	-$825K+18.0%	-$1.0M+40.8%	-$1.7M
Financing Cash Flow	$117.2M+2267.0%	-$5.4M-9.5%	-$4.9M-38076.9%	$13K-94.3%	$230K+103.5%	-$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$5.0M	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$33.0M-6510.5%	$514K+127.0%	-$1.9M-125.7%	$7.4M+15.6%	$6.4M+30.2%	$4.9M-12.3%	$5.6M+26.6%	$4.4M
Capital Expenditures	N/A	N/A	N/A	$3K	$0-100.0%	$44K+1000.0%	$4K-88.6%	$35K
Free Cash Flow	N/A	N/A	N/A	$7.4M+15.5%	$6.4M+31.4%	$4.9M-13.0%	$5.6M+27.5%	$4.4M
Investing Cash Flow	-$47.8M+68.1%	-$149.7M-71.4%	-$87.3M+27.8%	-$121.0M-1334.5%	-$8.4M+86.1%	-$60.5M-74550.6%	-$81K-100.4%	$18.6M
Financing Cash Flow	$77.4M-49.4%	$152.9M+69.6%	$90.1M-22.2%	$115.8M+9188.1%	$1.2M+1023.4%	$111K+909.1%	$11K+100.3%	-$3.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SMLR Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	91.5%+1.8pp	89.8%-2.7pp	92.5%+4.1pp	88.4%-2.9pp	91.3%+2.5pp	88.8%
Operating Margin	37.2%+4.5pp	32.6%+2.3pp	30.3%-6.3pp	36.7%-4.7pp	41.3%+8.7pp	32.7%
Net Margin	72.7%+42.5pp	30.2%+4.9pp	25.3%-7.2pp	32.5%-3.8pp	36.3%-9.7pp	46.0%
Return on Equity	17.7%-11.0pp	28.7%+2.9pp	25.7%-12.1pp	37.8%-9.2pp	47.0%-68.4pp	115.4%
Return on Assets	17.1%-9.3pp	26.4%+3.5pp	22.9%-11.1pp	34.0%-6.5pp	40.4%-42.0pp	82.5%
Current Ratio	3.59-7.0	10.64+3.5	7.13-2.2	9.33+3.4	5.89+3.7	2.20
Debt-to-Equity	0.04-0.0	0.09-0.0	0.13+0.0	0.11-0.1	0.16-0.2	0.40
FCF Margin	43.3%+12.5pp	30.8%+0.8pp	30.0%+0.3pp	29.7%-9.1pp	38.8%+0.5pp	38.3%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	91.5%+0.5pp	91.0%+1.6pp	89.4%-1.7pp	91.1%-0.3pp	91.4%+0.1pp	91.3%-0.8pp	92.2%+14.6pp	77.5%
Operating Margin	-72.0%-47.0pp	-25.0%+327.0pp	-352.0%-380.6pp	28.5%-9.0pp	37.5%+0.5pp	37.0%-6.9pp	43.9%+27.1pp	16.7%
Net Margin	225.6%-588.9pp	814.6%+1546.9pp	-732.3%-967.6pp	235.3%+193.8pp	41.5%+41.4pp	0.1%-38.1pp	38.2%+10.2pp	28.0%
Return on Equity	3.7%-13.8pp	17.5%+57.5pp	-40.0%-52.7pp	12.7%+6.1pp	6.6%+6.6pp	0.0%-7.8pp	7.8%+1.9pp	5.9%
Return on Assets	2.8%-10.0pp	12.8%+34.9pp	-22.1%-34.2pp	12.2%+6.1pp	6.1%+6.1pp	0.0%-7.2pp	7.2%+1.8pp	5.4%
Current Ratio	1.97+1.4	0.60+0.1	0.52-3.1	3.59+0.5	3.14-0.6	3.72-8.5	12.18+1.5	10.64
Debt-to-Equity	0.30-0.1	0.36-0.5	0.81+0.8	0.04-0.0	0.080.0	0.080.0	0.08-0.0	0.09
FCF Margin	N/A	N/A	N/A	59.8%+12.3pp	47.5%+13.7pp	33.8%-1.5pp	35.3%+6.1pp	29.3%

Similar Companies

$740.6M

$614.5M

$444.3M

$209.5M

$817.7M

Frequently Asked Questions

What is Semler Scientific Inc's annual revenue?

Semler Scientific Inc (SMLR) reported $56.3M in total revenue for fiscal year 2024. This represents a -17.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Semler Scientific Inc's revenue growing?

Semler Scientific Inc (SMLR) revenue declined by 17.4% year-over-year, from $68.2M to $56.3M in fiscal year 2024.

Is Semler Scientific Inc profitable?

Yes, Semler Scientific Inc (SMLR) reported a net income of $40.9M in fiscal year 2024, with a net profit margin of 72.7%.

What is Semler Scientific Inc's EBITDA?

Semler Scientific Inc (SMLR) had EBITDA of $21.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Semler Scientific Inc's gross margin?

Semler Scientific Inc (SMLR) had a gross margin of 91.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Semler Scientific Inc's operating margin?

Semler Scientific Inc (SMLR) had an operating margin of 37.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Semler Scientific Inc's net profit margin?

Semler Scientific Inc (SMLR) had a net profit margin of 72.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Semler Scientific Inc's return on equity (ROE)?

Semler Scientific Inc (SMLR) has a return on equity of 17.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Semler Scientific Inc's free cash flow?

Semler Scientific Inc (SMLR) generated $24.4M in free cash flow during fiscal year 2024. This represents a 16.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Semler Scientific Inc's operating cash flow?

Semler Scientific Inc (SMLR) generated $24.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Semler Scientific Inc's total assets?

Semler Scientific Inc (SMLR) had $239.8M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Semler Scientific Inc's capital expenditures?

Semler Scientific Inc (SMLR) invested $51K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Semler Scientific Inc spend on research and development?

Semler Scientific Inc (SMLR) invested $4.8M in research and development during fiscal year 2024.

How many shares does Semler Scientific Inc have outstanding?

Semler Scientific Inc (SMLR) had 10M shares outstanding as of fiscal year 2024.

What is Semler Scientific Inc's current ratio?

Semler Scientific Inc (SMLR) had a current ratio of 3.59 as of fiscal year 2024, which is generally considered healthy.

What is Semler Scientific Inc's debt-to-equity ratio?

Semler Scientific Inc (SMLR) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Semler Scientific Inc's return on assets (ROA)?

Semler Scientific Inc (SMLR) had a return on assets of 17.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Semler Scientific Inc's Altman Z-Score?

Semler Scientific Inc (SMLR) has an Altman Z-Score of 21.73, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Semler Scientific Inc's Piotroski F-Score?

Semler Scientific Inc (SMLR) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Semler Scientific Inc's earnings high quality?

Semler Scientific Inc (SMLR) has an earnings quality ratio of 0.60x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Semler Scientific Inc?

Semler Scientific Inc (SMLR) scores 78 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.